Seres Therapeutics, Inc.

MCRB

$19.64

Name : Seres Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $171,939,744.00

EPSttm : -6.79

Seres Therapeutics, Inc.

$19.64

2.24%

$0.45

Float Short %

14.65

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

0.91

EPS Last/This Y

1.34

EPS This/Next Y

-11.03

Price

19.5

Target Price

Analyst Recom

1.67

Performance Q

59.03

Relative Volume

0.41

Beta

0.2

Ticker: MCRB

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-09	MCRB	18.64	0.10	0.55	18701
2025-09-10	MCRB	17.58	0.12	0.19	19690
2025-09-11	MCRB	17.53	0.11	0.01	19993
2025-09-12	MCRB	15.91	0.12	0.10	19719
2025-09-15	MCRB	15.56	0.11	0.01	20077
2025-09-16	MCRB	17.39	0.11	0.18	20575
2025-09-17	MCRB	17.61	0.11361457334612	0.85245901639344	20907
2025-09-18	MCRB	18	0.11	0.36	20909
2025-09-22	MCRB	16.51	0.09	0.14	19280
2025-09-23	MCRB	17.44	0.09	0.11	19308
2025-09-24	MCRB	19.37	0.09	0.03	19484
2025-09-25	MCRB	19.05	0.09	0.10	20109
2025-09-26	MCRB	18.9	0.09	0.00	20125
2025-09-29	MCRB	18.81	0.09	0.01	20132
2025-09-30	MCRB	19.42	0.09	0.20	20144
2025-10-01	MCRB	20.25	0.09	0.03	19609
2025-10-02	MCRB	20.94	0.09	0.01	19728
2025-10-03	MCRB	20.73	0.09	0.07	19683
2025-10-06	MCRB	21	0.09	0.02	19639
2025-10-07	MCRB	20.11	0.09	0.00	19707
2025-10-08	MCRB	19.48	0.09	0.17	20752
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-09	MCRB	18.60	118.8	-	1.75
2025-09-10	MCRB	17.59	118.8	-	1.75
2025-09-11	MCRB	17.57	118.8	-	1.75
2025-09-12	MCRB	15.93	118.8	-	1.75
2025-09-15	MCRB	15.62	118.8	-	1.75
2025-09-16	MCRB	17.40	118.8	-	1.75
2025-09-17	MCRB	17.59	118.8	-	1.75
2025-09-18	MCRB	18.08	118.8	-	1.75
2025-09-19	MCRB	17.43	118.8	-	1.75
2025-09-22	MCRB	16.52	118.8	-	1.75
2025-09-23	MCRB	17.44	118.8	-	1.75
2025-09-24	MCRB	19.52	118.8	-	1.75
2025-09-25	MCRB	18.90	118.8	-	1.75
2025-09-26	MCRB	18.93	118.8	-	1.34
2025-09-29	MCRB	18.71	119.4	-	1.34
2025-09-30	MCRB	19.29	119.4	-	1.34
2025-10-01	MCRB	20.55	119.4	-	1.34
2025-10-02	MCRB	21.10	119.4	-	1.34
2025-10-03	MCRB	20.59	119.4	-	1.34
2025-10-06	MCRB	21.00	119.4	-	1.34
2025-10-07	MCRB	20.11	119.4	-	1.34
2025-10-08	MCRB	19.50	119.4	-	1.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-09	MCRB	-0.04	-50.21	16.04
2025-09-10	MCRB	-0.04	-50.21	16.04
2025-09-11	MCRB	-0.04	-50.21	15.69
2025-09-12	MCRB	-0.04	-50.21	15.67
2025-09-15	MCRB	-0.04	-50.21	15.67
2025-09-16	MCRB	-0.04	-50.21	15.67
2025-09-17	MCRB	-0.04	-50.21	15.67
2025-09-18	MCRB	-0.04	-50.21	15.67
2025-09-19	MCRB	-0.04	-50.21	15.64
2025-09-22	MCRB	-0.04	-50.21	15.64
2025-09-23	MCRB	-0.04	-50.21	15.64
2025-09-24	MCRB	-0.04	-50.21	15.64
2025-09-25	MCRB	-0.04	-50.21	14.47
2025-09-26	MCRB	-0.04	-50.21	14.47
2025-09-29	MCRB	-0.04	-50.21	14.47
2025-09-30	MCRB	-0.04	-50.21	14.47
2025-10-01	MCRB	-0.04	-50.21	14.47
2025-10-02	MCRB	-0.04	-50.21	14.47
2025-10-03	MCRB	-0.04	-50.21	14.47
2025-10-06	MCRB	-0.04	-10.37	14.65
2025-10-07	MCRB	-0.04	-10.37	14.65
2025-10-08	MCRB	-0.04	-10.37	14.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-2.27

Avg. EPS Est. Current Quarter

1.28

Avg. EPS Est. Next Quarter

-1.36

Insider Transactions

-0.04

Institutional Transactions

-10.37

Beta

0.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.5

Max Drawdown 5-Year %

-99.1

Target Price

P/E

Forward P/E

PEG

P/S

P/B

5.22

P/Free Cash Flow

EPS

-7.92

Average EPS Est. Cur. Y

1.34

EPS Next Y. (Est.)

-9.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.41

Return on Equity vs Sector %

235.7

Return on Equity vs Industry %

249.4

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.41

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y